Literature DB >> 26780231

Effect of sarcopenia and visceral obesity on mortality and pancreatic fistula following pancreatic cancer surgery.

N Pecorelli1, G Carrara1, F De Cobelli2, G Cristel2, A Damascelli2, G Balzano1, L Beretta3, M Braga1.   

Abstract

BACKGROUND: Analytical morphometric assessment has recently been proposed to improve preoperative risk stratification. However, the relationship between body composition and outcomes following pancreaticoduodenectomy is still unclear. The aim of this study was to assess the impact of body composition on outcomes in patients undergoing pancreaticoduodenectomy for cancer.
METHODS: Body composition parameters including total abdominal muscle area (TAMA) and visceral fat area (VFA) were assessed by preoperative staging CT in patients undergoing pancreaticoduodenectomy for cancer. Perioperative variables and postoperative outcomes (mortality or postoperative pancreatic fistula) were collected prospectively in the institutional pancreatic surgery database. Optimal stratification was used to determine the best cut-off values for anthropometric measures. Multivariable analysis was performed to identify independent predictors of 60-day mortality and pancreatic fistula.
RESULTS: Of 202 included patients, 132 (65·3 per cent) were classified as sarcopenic. There were 12 postoperative deaths (5·9 per cent), major complications developed in 40 patients (19·8 per cent) and pancreatic fistula in 48 (23·8 per cent). In multivariable analysis, a VFA/TAMA ratio exceeding 3·2 and American Society of Anesthesiologists grade III were the strongest predictors of mortality (odds ratio (OR) 6·76 and 6·10 respectively; both P < 0·001). Among patients who developed major complications, survivors had a significantly lower VFA/TAMA ratio than non-survivors (P = 0·017). VFA was an independent predictor of pancreatic fistula (optimal cut-off 167 cm(2) : OR 4·05; P < 0·001).
CONCLUSION: Sarcopenia is common among patients undergoing pancreaticoduodenectomy. The combination of visceral obesity and sarcopenia was the best predictor of postoperative death, whereas VFA was an independent predictor of pancreatic fistula.
© 2016 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 26780231     DOI: 10.1002/bjs.10063

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  58 in total

1.  Predictive value of sarcopenia and visceral obesity for postoperative pancreatic fistula after pancreaticoduodenectomy analyzed on clinically acquired CT and MRI.

Authors:  Minji Jang; Hyung Woo Park; Jimi Huh; Jong Hwa Lee; Yoong Ki Jeong; Yang Won Nah; Jisuk Park; Kyung Won Kim
Journal:  Eur Radiol       Date:  2018-11-07       Impact factor: 5.315

2.  A novel preoperative predictor of pancreatic fistula using computed tomography after distal pancreatectomy with staple closure.

Authors:  Yasunari Fukuda; Daisaku Yamada; Hidetoshi Eguchi; Yoshifumi Iwagami; Takehiro Noda; Tadafumi Asaoka; Hiroshi Wada; Koichi Kawamoto; Kunihito Gotoh; Masaki Mori; Yuichiro Doki
Journal:  Surg Today       Date:  2017-03-06       Impact factor: 2.549

Review 3.  Enhanced recovery pathways in pancreatic surgery: State of the art.

Authors:  Nicolò Pecorelli; Sara Nobile; Stefano Partelli; Luca Cardinali; Stefano Crippa; Gianpaolo Balzano; Luigi Beretta; Massimo Falconi
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

4.  Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy.

Authors:  Jordan M Cloyd; Graciela M Nogueras-González; Laura R Prakash; Maria Q B Petzel; Nathan H Parker; An T Ngo-Huang; David Fogelman; Jason W Denbo; Naveen Garg; Michael P Kim; Jeffrey E Lee; Ching-Wei D Tzeng; Jason B Fleming; Matthew H G Katz
Journal:  J Gastrointest Surg       Date:  2017-12-11       Impact factor: 3.452

5.  Impact of the preoperative body composition indexes on intraoperative blood loss in patients undergoing pancreatoduodenectomy.

Authors:  Kenta Ishii; Yukihiro Yokoyama; Tomoki Ebata; Tsuyoshi Igami; Takashi Mizuno; Junpei Yamaguchi; Shunsuke Onoe; Nobuyuki Watanabe; Masato Nagino
Journal:  Surg Today       Date:  2020-06-20       Impact factor: 2.549

6.  Sarcopenia Affects Systemic and Local Immune System and Impacts Postoperative Outcome in Patients with Extrahepatic Cholangiocarcinoma.

Authors:  Yuki Kitano; Yo-Ichi Yamashita; Yoichi Saito; Shigeki Nakagawa; Hirohisa Okabe; Katsunori Imai; Yoshihiro Komohara; Yuji Miyamoto; Akira Chikamoto; Takatoshi Ishiko; Hideo Baba
Journal:  World J Surg       Date:  2019-09       Impact factor: 3.352

7.  Correlation between the skeletal muscle index and surgical outcomes of pancreaticoduodenectomy.

Authors:  Kenta Sui; Takehiro Okabayshi; Jun Iwata; Sojiro Morita; Tatsuaki Sumiyoshi; Tatsuo Iiyama; Yasuhiro Shimada
Journal:  Surg Today       Date:  2017-12-28       Impact factor: 2.549

8.  Impact of Visceral Obesity and Sarcopenia on Short-Term Outcomes After Colorectal Cancer Surgery.

Authors:  Wei-Zhe Chen; Xiao-Dong Chen; Liang-Liang Ma; Feng-Min Zhang; Ji Lin; Cheng-Le Zhuang; Zhen Yu; Xiao-Lei Chen; Xiao-Xi Chen
Journal:  Dig Dis Sci       Date:  2018-03-16       Impact factor: 3.199

9.  Sarcopenia predicts 1-year mortality in elderly patients undergoing curative gastrectomy for gastric cancer: a prospective study.

Authors:  Dong-Dong Huang; Xiao-Xi Chen; Xi-Yi Chen; Su-Lin Wang; Xian Shen; Xiao-Lei Chen; Zhen Yu; Cheng-Le Zhuang
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-29       Impact factor: 4.553

10.  Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer.

Authors:  M P Petrova; I S Donev; M A Radanova; M I Eneva; E G Dimitrova; G N Valchev; V T Minchev; M S Taushanova; M V Boneva; T S Karanikolova; R B Gencheva; G A Zhbantov; A I Ivanova; C V Timcheva; B P Pavlov; V G Megdanova; B S Robev; N V Conev
Journal:  Clin Exp Immunol       Date:  2020-08-26       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.